Autres langues Titan Pharmaceuticals

Actions

TTNP

US8883147055

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
0,6498 ^USD	+2,57%		+30,46%	-85,90%

03/10/25	Clôture de la fusion entre Titan Pharmaceuticals et Black Titan Corporation	RE
01/10/25	Titan Pharmaceuticals, Inc. nomme Chay Weei Jye en tant qu'unique administrateur et secrétaire par intérim, à compter du 1er octobre 2025	CI

Autres langues

03/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation
01/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025
01/10/25	Titan Pharmaceuticals, Inc.(NasdaqCM:TTNP) dropped from NASDAQ Composite Index
01/10/25	Ke Sdn. Bhd. completed the acquisition of Titan Pharmaceuticals, Inc. in a reverse merger transaction.
15/08/25	Titan Pharmaceuticals: Q2 Earnings Snapshot
14/08/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
06/08/25	TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP
27/06/25	Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock
27/06/25	Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.C
24/06/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Blue Harbour Asset Management L.L.C
03/06/25	Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.
15/05/25	Titan Pharmaceuticals: Q1 Earnings Snapshot
14/05/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
11/04/25	Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock
11/04/25	Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock
11/04/25	Titan Pharmaceuticals, Inc. announced that it has received $1 million in funding
01/04/25	Titan Pharmaceuticals, Inc. Appoints Gabriel Loh as an Independent Director and Member of the Audit Committee
29/03/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $1 million in funding
20/03/25	Titan Pharmaceuticals: Q4 Earnings Snapshot
20/03/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024
20/03/25	Titan Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
03/01/25	Titan Pharmaceuticals: Q3 Earnings Snapshot
03/01/25	Titan Pharmaceuticals : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)
03/01/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
06/12/24	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as Chief Executive Officer